RFK Jr. to Allow Broad Use of Unapproved Peptide Injections

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. is proposing to expand access to certain unapproved peptide injections through specialized compounding pharmacies. The proposal could allow broader use of six peptides, including BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax, which are promoted by some wellness providers for purposes such as tissue repair, inflammation, metabolic health, and recovery. However, these substances have not been approved by the U.S. Food and Drug Administration (FDA) as safe and effective treatments for these uses. Supporters of the proposal argue that expanding access through pharmacies could provide patients with more controlled options under medical supervision, while critics warn that the safety and effectiveness of many peptides remain uncertain because of limited clinical evidence. Potential concerns include contamination, allergic reactions, and other serious health risks. The proposal could change how federal regulators enforce restrictions on certain compounded peptide products, but it would not mean that the substances have received FDA approval. The issue has sparked debate over patient choice, medical research, and the importance of ensuring that treatments meet established safety and quality standards.